ERBB2 and breast carcinoma: The recognition of the prognostic relevance of pCR in HER2+ breast cancer was gleaned from long-term follow-up of neoadjuvant clinical trials as well as real-world evidence, with consistent observations of significantly worse event-free survival for patients with HER2+ disease that do not achieve a pCR after neoadjuvant therapy.